Recent investigations have converged on the convergence of GLP-1|GIP|GCGR stimulant therapies and dopaminergic signaling. While GLP activators are increasingly employed for treating type 2 T2DM, their unexpected effects on reinforcement circuits, specifically governed by dopamine systems, are attracting substantial attention. This paper presents a